2型糖尿病与代谢功能障碍相关脂肪性肝病的流行病学、筛查与共同管理
代谢功能障碍相关脂肪性肝病(MASLD)与2型糖尿病(T2DM)因共享致病机制而紧密关联,二者共存增加肝脏不良结局及肝外结局负担。本综述阐述二者流行病学、T2DM患者肝纤维化评估、MASLD人群血糖监测,并提供综合共同管理策略,强调多学科协作,并提及多项随机对照试验为治疗提供依据。
要点
- MASLD与T2DM共享致病机制,共存增加肝脏不良结局和肝外结局负担。
- T2DM合并MASLD的有效评估与管理需多学科协作。
- 综述涵盖T2DM患者肝纤维化评估、MASLD人群血糖监测及共同管理策略。
核心结论
- MASLD与T2DM因共享致病机制而强关联,二者共存增加肝脏不良结局风险并加重肝外结局负担,构成重大公共卫生问题。
- T2DM合并MASLD的有效评估与管理需多学科协作,多项随机对照试验为治疗提供依据。
研究设计与样本
- 综述,阐述T2DM与MASLD交织的流行病学、T2DM患者肝纤维化评估、MASLD人群血糖监测及综合共同管理策略。
主要发现
- MASLD(既往称NAFLD)日益被视为全球常见疾病负担。
- T2DM被认为是MASLD发生的重要促进因素。
- MASLD与T2DM共存增加肝脏相关不良结局风险,并加重肝外结局负担。
临床怎么用
- T2DM合并MASLD的有效评估与管理需多学科协作。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as NAFLD, is increasingly recognized as a prevalent global burden. Type 2 diabetes mellitus (T2DM), another important metabolic disease, is considered a major contributor to the development of MASLD. MASLD and T2DM have a strong association with each other due to shared pathogenic mechanisms. The co-existence of the 2 diseases increases the risk of liver-related adverse outcomes and imposes a heavier burden on extrahepatic outcomes, representing a substantial public health issue. Effective assessment and management of T2DM combined with MASLD necessitate a multidisciplinary approach. The emergence of numerous RCTs has shed light on the treatment of T2DM combined with MASLD. This review uncovers the epidemiology of the intertwined T2DM and MASLD, offers insights into the evaluation of hepatic fibrosis in patients with T2DM, glucose monitoring in the MASLD population, and provides comprehensive co-management strategies for addressing both diseases.
引用
- Qi X, Li J, Caussy C, et al. Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease. Hepatology. 2026. PMID: 38722246. doi:10.1097/HEP.0000000000000913
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。